This approval does not yet have a date. The letter says so directly: under 21 U.S.C. 355(x), the date of approval shall be whenever the DEA publishes its interim final scheduling notice. Everything downstream hangs off that single act, including the right to market, the Orange Book listing, the thirty-day window to file patent information, and the anniversary from which annual reporting is counted. Takeda holds a first-in-class approval it cannot sell, in a category where it faces no competitor, and the exclusivity clock has not started running.

• The schedule will shape prescribing more than the label does. The DEA has not yet set the tier, and the gap between the plausible outcomes is not academic. Scheduling determines refill limits, in-person requirements, quantity restrictions and how much administrative friction a neurologist absorbs per patient per year, in a lifelong condition that typically declares itself in adolescence and is managed for decades. When the Federal Register notice lands, read the schedule before the date. That is the variable that decides real-world uptake, and it is the one no press release will lead with.
• The review was unusually clean and the letter is unusually explicit about why. No advisory committee was convened because the evaluation raised no significant or unexpected safety or efficacy issues, outside expertise was not necessary, and there were no controversial issues to discuss. Eight months from submission to approval for a first-in-class mechanism in a rare neuropsychiatric disease is a strong result. Note also what orphan designation removed: the PREA paediatric assessment does not apply, so the label is adults only and no paediatric programme is compelled in a disease that usually begins in the teens. That gap gets filled commercially or not at all.
• Read the postmarketing requirements for what the agency could not settle. Three of the four concern pregnancy and lactation, and FDA states plainly that neither spontaneous adverse event reporting nor its active surveillance system would be sufficient to identify the risk. That is the agency demanding purpose-built evidence rather than passive monitoring, in a condition that disproportionately affects young adults. The retrospective cohort’s final report is due April 2039 and the prospective registry’s in February 2038, so the reproductive safety question stays formally open for over a decade while the product is on the market and, eventually, while generics are contemplating entry.